DANVERS, Mass.--(BUSINESS WIRE)-- The United States Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for Impella RP to include patients suffering from COVID-19 ...
WASHINGTON -- Abiomed Inc., a leading provider of breakthrough heart support technologies, today announced clinical trial results from RECOVER RIGHT, an Investigational Device Exemption (IDE) study of ...
Please provide your email address to receive an email when new articles are posted on . Abiomed is recalling specific Impella 5.5 left ventricular device systems due to product leakage. The FDA ...
Today the US Food and Drug Administration released an update saying that final postapproval study (PAS) results for the Impella RP system (Abiomed) now alleviate concerns about a potential mortality ...
PARIS--(BUSINESS WIRE)-- Abiomed (NASDAQ: ABMD) announces today that the Impella CP ® with SmartAssist technology, which is designed to improve patient outcomes with advanced algorithms and simplified ...
WASHINGTON, March 19, 2017 (GLOBE NEWSWIRE) -- Data from Abiomed’s (NASDAQ:ABMD) Impella ® Quality (IQ) Assurance Program, which includes the IQ Database and cVAD Registry, was presented today as late ...
The Impella heart pump is a small pump that a healthcare professional can insert without surgery. It can help maintain blood flow in people who have CAD, are recovering from cardiogenic shock, or are ...
A new investigational percutaneous ventricular assist device (pVAD) is ready to challenge Johnson & Johnson's Impella heart pumps. Supira Medical's Supira pVAD uses a smaller introducer sheath ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results